| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,176 | 0,194 | 20:13 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.11. | BioInvent International: BioInvent to Participate in Upcoming Investor Conferences | 263 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 9, 2026 / BioInvent International AB ("BioInvent") (STO:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that representatives... ► Artikel lesen | |
| 05.11. | BioInvent International AB: BioInvent announces final terms for the Rights Issue of approximately SEK 430 million and informs that the Issue is fully guaranteed by additional top guarantee undertakings | 165 | GlobeNewswire (Europe) | Not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, Singapore, South Africa or any other jurisdiction where such... ► Artikel lesen | |
| BIOINVENT Aktie jetzt für 0€ handeln | |||||
| 05.11. | Transgene S.A.: First Patient Dosed in Phase 1 Trial Evaluating Transgene's and BioInvent's BT-001 in Patients with Rectal Cancer | 1 | GlobeNewswire (USA) | ||
| 28.10. | BioInvent International AB: BioInvent International AB: Interim report January - September, 2026 | 150 | GlobeNewswire (Europe) | "Our clinical portfolio remains focused on two targets, TNFR2 and Fc?RIIB, but with a current priority on BI-1808 in cancers where patients have few effective options. With the planned rights issue... ► Artikel lesen | |
| 28.10. | BioInvent International AB: BioInvent resolves on a rights issue of approximately SEK 430 million subject to approval by an extraordinary general meeting and earlier publication of interim report January - September 2026 | 208 | GlobeNewswire (Europe) | Not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, Singapore, South Africa or any other jurisdiction where such... ► Artikel lesen | |
| 27.10. | BioInvent International: Invitation to Presentation of BioInvent's Interim Report January - September 2026 | 321 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 27, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts, and the press to a presentation of the interim report January-September... ► Artikel lesen | |
| 24.10. | BioInvent International: BioInvent's BI-1808 and KEYTRUDA Induce Durable Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer | 959 | ACCESS Newswire | BioInvent International (STO:BINV) - Updated efficacy data in 34 evaluable patients with a chemotherapy-free regimen; randomized Part C will add BI-1808 to the new standard of care24% objective response... ► Artikel lesen | |
| 19.10. | BioInvent International: BioInvent To Present BI-1808 Data in Platinum-Resistant Recurrent Ovarian Cancer at ESMO 2026 | 1.928 | ACCESS Newswire | BioInvent International (STO:BINV) - Poster with the title "From Modest to Meaningful: Targeting TNFR2 with BI-1808 to Unlock Checkpoint Inhibitor Efficacy in Platinum-Resistant Recurrent Ovarian Cancer... ► Artikel lesen | |
| 15.10. | BioInvent International: BioInvent Announces Publication of First-in-Human BI-1808 Data in Clinical Cancer Research | 618 | ACCESS Newswire | BI-1808 monotherapy demonstrated an excellent safety profile and evidence of single-agent anti-tumor activity, correlating with tumor-infiltrating CD8+ T cells and inducing antitumor immunity.Translational... ► Artikel lesen | |
| 12.10. | BioInvent International AB Announces that its CFO will Retire in 2027 | 380 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 12, 2026 / BioInvent International AB ("BioInvent") (STO:BINV), a leader in the discovery of novel immunomodulatory antibodies, today announced that the company's... ► Artikel lesen | |
| 27.08. | BioInvent International AB: Interim report January - June 2026 | 575 | GlobeNewswire (Europe) | "During the second quarter, both of our lead programs generated clinical data that further strengthened their competitive positioning. BI-1808 (anti-TNFR2) reported new results in two distinct indications... ► Artikel lesen | |
| 20.08. | BioInvent International: BioInvent Announces Publication of Preclinical Manuscript on BI-1808 and BI-1910 in Cancer Research | 997 | ACCESS Newswire | Preclinical manuscript that characterizes the mechanism of action, broad antitumor efficacy, and immune-activating properties of BI-1808 and BI-1910 across diverse tumor microenvironmentsData demonstrates... ► Artikel lesen | |
| 07.08. | BioInvent International: BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer | 996 | ACCESS Newswire | FDA Fast Track Designation granted for BI-1808, a first-in-class anti-TNFR2 antibody, for the treatment of ovarian cancer.BI-1808 in combination with pembrolizumab demonstrated a 24% confirmed ORR and... ► Artikel lesen | |
| 28.07. | BioInvent International: BioInvent Publication in JECCR: Tailored FcyR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models | 655 | ACCESS Newswire | LUND, SE / ACCESS Newswire / July 28, 2026 / BioInvent International (STO:BINV)Preclinical proof-of-concept data support two distinct FcyR-blockade strategies to enhance cancer antibody therapies and... ► Artikel lesen | |
| 17.07. | BioInvent International: BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026 | 625 | ACCESS Newswire | LUND, SE / ACCESS Newswire / July 17, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that its... ► Artikel lesen | |
| 11.06. | BioInvent International: BioInvent's TNFR2 Antibody BI-1808 Delivers Meaningful Responses and Immune Activation as Single Agent and in Combination with KEYTRUDA in Advanced CTCL | 871 | ACCESS Newswire | BioInvent will host an in-person KOL lunch briefing (11:45 a.m. - 2:00 p.m. CEST / 5:45 - 8:00 a.m. EDT) in conjunction with EHA 2026 Congress today (virtual event link here)BI-1808 monotherapy achieves... ► Artikel lesen | |
| 11.06. | BioInvent International: BioInvent's BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC | 648 | ACCESS Newswire | BioInvent will host an in-person KOL lunch briefing (11:45 a.m. - 2:00 p.m. CEST / 5:45 - 8:00 a.m. EDT) in conjunction with EHA 2026 Congress today (virtual event link here)83% ORR across all evaluable... ► Artikel lesen | |
| 01.06. | BioInvent International: BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology | 719 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 1, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it... ► Artikel lesen | |
| 21.05. | BioInvent International: BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA in Advanced Ovarian Cancer at ASCO | 931 | ACCESS Newswire | BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by... ► Artikel lesen | |
| 20.05. | BioInvent International: BioInvent to Host Virtual KOL Event to Discuss BI-1808 for the Treatment of Ovarian Cancer, on May 27, 2026 | 1.105 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 20, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 73,60 | -0,81 % | BioNTech Aktie: Wehe, diese Marken halten nicht... | Dreimal hat die BioNTech Aktie seit Ende Oktober die Zone um 85 Dollar getestet, dreimal hat sie gehalten. Am Donnerstag war es wieder so weit, und diesmal schloss der Kurs mitten in der Kernzone. Seit... ► Artikel lesen | |
| EVOTEC | 2,506 | -8,21 % | Evotec-Aktie mit -95% - lohnt sich jetzt der Einstieg? | Die Evotec-Aktie ist am Freitag um -5,06% auf 2,97 € gefallen und bleibt damit fest in der Hand der Verkäufer. Der Kurs bewegt sich inzwischen am unteren Rand des langfristigen Abwärtstrendkanals und... ► Artikel lesen | |
| BB BIOTECH | 56,50 | -0,18 % | Christian Koch, Leiter BB Biotech Team bei Bellevue Asset Management, im Interview | von Robert Jakob Moneycab.com: Herr Koch, acht bestehende Beteiligungen verkauft, zwölf neue Positionen aufgebaut, das sieht nach einer grösseren Rochade aus? Die Veränderungen spiegeln unser aktives... ► Artikel lesen | |
| MEDIGENE | 0,003 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 45,070 | -0,40 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| MODERNA | 177,38 | -2,29 % | Moderna nach 300 % Rallye: Droht jetzt eine größere Korrektur? | Seit August verzeichnete Moderna einen deutlichen Kursanstieg, auf den zuletzt eine Zwischenkorrektur folgte. Die bisher intakte Folge höherer Hochs und Tiefs sowie die zuletzt verteidigte 50-Tage-Linie... ► Artikel lesen | |
| AMGEN | 400,00 | +0,02 % | Dividendenbekanntmachungen (20.11.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0683 EUR AGNT INC US30212W1009 0,05 USD 0,0455 EUR AMGEN INC US0311621009 2... ► Artikel lesen | |
| VALNEVA | 2,345 | -2,98 % | Valneva: Positive Shigella-Daten - was jetzt für die Aktie zählt | ||
| EPIGENOMICS | 0,870 | 0,00 % | PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
Epigenomics AG: Veröffentlichung nach -- 40 Abs. 1 WpHG
Heidelberg (pta000/26.10.2026/15:00... ► Artikel lesen | |
| NOVAVAX | 6,930 | -1,56 % | Novavax: Prognose erhöht - worauf es jetzt ankommt | ||
| BIOGEN | 227,75 | +1,11 % | 10,7 Billionen Dollar (!) Schaden: Lilly, Biogen, Jazz Pharmaceuticals und NeuroThera greifen in diesem Markt an! | ||
| BIOFRONTERA | 2,710 | -3,21 % | Biofrontera: Liquidität unter Druck - was jetzt zählt | ||
| HEIDELBERG PHARMA | 2,010 | -1,47 % | Formycon gegen Heidelberg Pharma gegen Medios: Das Biotech-Nebenwert-Duell - Formycon liegt beim Analystenbild vorn | ||
| ILLUMINA | 176,06 | -3,71 % | Illumina Stock Surges 74.8% in a Year: What's Fueling the Drive? | ||
| NANOREPRO | 1,440 | -0,35 % | NanoRepro nach H1-Zahlen und Drogerie-Deal: Diese Marke entscheidet jetzt |